Illumina stock
ILMNNASDAQIllumina, Inc., HealthcareISIN US4523271090
70Score 70 out of 100, Strong
Price and trend
64 / 100
Price history
+74% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 31).
The price is 27% below its 52-week high. Largest decline in 20 years: 86% (August 2021 to April 2025).
Chart figures for advanced users
- SMA 50$249.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$178.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)31
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$114.44
- The lowest closing price of the last twelve months.
- Resistance$293.69
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Illumina, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $32.2B, is number 10 of 37 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $4.63B (up 6.7%) and adjusted earnings per share of $5.42 (up 11.7%).
- MEQIRI Score 70 out of 100 (Strong): rank 139 of 714 in Healthcare, median 53.
Show more
- The P/E is 36.6 (Medical (Diagnostics & Research) median 33.7, own median of recent years 46.8).
- Our model puts fair value at $175.12, with the price 22% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 19.7% over the last 12 months, Medical (Diagnostics & Research) median 6.7%.Profitability 91
- High return on capitalReturn on invested capital 18.2% in fiscal 2025, Medical (Diagnostics & Research) median 6.4%.Profitability 91
- Earnings turn into cashFree cash flow 118% of earnings over the last 12 months.Fundamentals 83
Weaknesses
- Volatile share priceVolatility 48% a year over the last 12 months.
Its standout strengths are profitability and fundamentals, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $125.09 and expensive above $291.87 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $154.15 (cash-flow model) and $196.09 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $162.87, at 8.3% it would be $192.85.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 27 Sep 2026, revenue rose 5.9% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 67%, operating 20%, net 20%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 29 Oct 2026EPS reported $1.62 (expected $1.36)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.42+1.1%
- Revenue
- $4.63B+0.1%
- Earnings per share
- $6.16+1.1%
- Revenue
- $4.95B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.3%2026 guidance for revenue growth and profitability raised, with operating margin guidance of 23.4% to 23.6% maintained; rest of world organic revenue growth now above 5%.
“We are maintaining our operating margin guidance of 23.4%-23.6%. With our higher revenue expectations for the year, this equates to diluted EPS guidance of $5.30-$5.40, an increase of $0.12 at the midpoint versus our prior guide, and a year-over-year growth of 11% at the midpoint and 14% ex acquisitions.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $658.78M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Meister Keith A.Sale
4 Nov 2026, Board
- Shares
- 50,000
- Price
- $227.17
- Value
- $11.36M
- Meister Keith A.Sale
3 Nov 2026, Board
- Shares
- 231,433
- Price
- $238.52
- Value
- $55.2M
- Meister Keith A.Sale
4 Sept 2026, Board
- Shares
- 119,501
- Price
- $218.40
- Value
- $26.1M
Show 23 more
- Meister Keith A.Sale
3 Sept 2026, Board
- Shares
- 75,951
- Price
- $218.23
- Value
- $16.57M
- Meister Keith A.Sale
2 Sept 2026, Board
- Shares
- 68,108
- Price
- $213.28
- Value
- $14.53M
- Meister Keith A.Sale
27 Aug 2026, Board
- Shares
- 138,379
- Price
- $228.89
- Value
- $31.67M
- Meister Keith A.Sale
26 Aug 2026, Board
- Shares
- 106,543
- Price
- $225.46
- Value
- $24.02M
- Meister Keith A.Sale
25 Aug 2026, Board
- Shares
- 131,019
- Price
- $225.51
- Value
- $29.55M
- Meister Keith A.Sale
21 Aug 2026, Board
- Shares
- 299,336
- Price
- $217.96
- Value
- $65.24M
- Meister Keith A.Sale
20 Aug 2026, Board
- Shares
- 285,238
- Price
- $213.86
- Value
- $61M
- Meister Keith A.Sale
19 Aug 2026, Board
- Shares
- 95,000
- Price
- $203.29
- Value
- $19.31M
- Wedel Christensen JakobSale
18 Aug 2026, SVP, Strategy/Corp Development
- Shares
- 1,033
- Price
- $191.52
- Value
- $197,840
- Meister Keith A.Sale
5 Aug 2026, Board
- Shares
- 283,269
- Price
- $199.61
- Value
- $56.54M
- Meister Keith A.Sale
4 Aug 2026, Board
- Shares
- 457,858
- Price
- $200.10
- Value
- $91.62M
- Davies Scott MSale
30 Jul 2026, Chief Legal Officer
- Shares
- 615
- Price
- $200.00
- Value
- $123,000
- Davies Scott MSale
25 Jun 2026, Chief Legal Officer
- Shares
- 615
- Price
- $180.00
- Value
- $110,700
- Leckman PatriciaSale
5 Jun 2026, SVP, Chief People Officer
- Shares
- 783
- Price
- $162.59
- Value
- $127,305
- Leckman PatriciaSale
2 Jun 2026, SVP, Chief People Officer
- Shares
- 784
- Price
- $162.08
- Value
- $127,068
- Meister Keith A.Sale
1 Jun 2026, Board
- Shares
- 235,000
- Price
- $163.63
- Value
- $38.45M
- Meister Keith A.Sale
29 May 2026, Board
- Shares
- 214,596
- Price
- $163.51
- Value
- $35.09M
- Davies Scott MSale
29 May 2026, Chief Legal Officer
- Shares
- 615
- Price
- $160.00
- Value
- $98,400
- Ericksen Scott DSale
29 May 2026, VP, Chief Accounting Officer
- Shares
- 500
- Price
- $160.00
- Value
- $80,000
- Meister Keith A.Sale
28 May 2026, Board
- Shares
- 220,000
- Price
- $152.27
- Value
- $33.5M
- Ericksen Scott DSale
28 May 2026, VP, Chief Accounting Officer
- Shares
- 1,500
- Price
- $150.10
- Value
- $225,150
- Meister Keith A.Sale
14 May 2026, Board
- Shares
- 104,393
- Price
- $145.34
- Value
- $15.17M
- Meister Keith A.Sale
13 May 2026, Board
- Shares
- 225,067
- Price
- $145.55
- Value
- $32.76M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Illumina
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- NateraNTRA $46.38B43
- WatersWAT $46.24B56
- IQVIA HoldingsIQV $45.24B67
- Mettler-Toledo InternationalMTD $35.04B76
- Labcorp HoldingsLH $30.23B64
- Quest DiagnosticsDGX $28.55B69
- Guardant HealthGH $20.94B45
- Medpace HoldingsMEDP $18.59B83
ETFs that hold Illumina
Held by 108 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 5.42% | 0.68% | €5.31M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 4.73% | 0.50% | €127.06M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 2.06% | 0.35% | €1.21B |
Show 5 more
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.73% | 0.49% | €318.39M |
| L&G Artificial Intelligence UCITS ETFXMLD | 1.73% | 0.49% | €1.96B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.66% | 0.25% | €44.3M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.52% | 0.40% | €1.49B |
| L&G ROBO Global Robotics and Automation UCITS ETFIROB | 1.51% | 0.80% | €1.58B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 27 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.